Targeted drugs
Phase 1Small molecule
Targeted drugs is one of 34 small molecule programs targeting IrAE. It is currently in Phase 1.
2
Indications
3
Total Trials
3
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
265 competitors in Hepatocellular Carcinoma
#DrugCompanyPhaseTrials
1Ibrance
PfizerPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Hepsera
GileadPreclinical
Doptelet
AAkarx
Preclinical
Miraclid
TTechpool Bio-Pharma Co., Ltd.
Preclinical
Vermox
WWim Janssens
Preclinical
Valemetostat
Bristol-Myers SquibbPreclinical
Alcohol
AstellasPreclinical
Chemotherapy Drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Preclinical
Targeted Therapy
FFudan University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hepatocellular Carcinoma2 trials
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma
Not yet recruiting·—·Phase 1·NCT06364787·18 enrolled
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody
Not yet recruiting·—·Phase 1·NCT06364800·18 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Targeted drugs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details